GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Inventories, Raw Materials & Components

RemeGen Co (HKSE:09995) Inventories, Raw Materials & Components : HK$364.5 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Inventories, Raw Materials & Components?

RemeGen Co's inventories, raw materials & components for the quarter that ended in Dec. 2023 was HK$364.5 Mil.

RemeGen Co's quarterly raw materials declined from Jun. 2023 (HK$420.8 Mil) to Sep. 2023 (HK$0.0 Mil) but then increased from Sep. 2023 (HK$0.0 Mil) to Dec. 2023 (HK$364.5 Mil).

RemeGen Co's annual raw materials increased from Dec. 2021 (HK$215.1 Mil) to Dec. 2022 (HK$316.0 Mil) and increased from Dec. 2022 (HK$316.0 Mil) to Dec. 2023 (HK$364.5 Mil).


RemeGen Co Inventories, Raw Materials & Components Historical Data

The historical data trend for RemeGen Co's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Inventories, Raw Materials & Components Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial 34.77 58.28 215.12 316.01 364.54

RemeGen Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 316.01 420.77 - 364.54 -

RemeGen Co Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


RemeGen Co (HKSE:09995) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Inventories, Raw Materials & Components
Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines